Mochida Pharmaceutical Co., Ltd.

Osaka Bioscience Institute

Tomokazu Matsusue

Kamon Shirakawa

Shoji Furusako

Yoshitaka Hosaka

Tetsushi Kawahara

Katsuki Naitoh

Motoyasu Honda

Hiroshi Takayama

Yumi Hotta

Maximiliano Vasquez

Shigekazu Nagata

Man Sung Co

Norio Nakamura

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.

Anti-platelet membrane glycoprotein VI monoclonal antibody

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof:

An anti-Fas ligand antibody capable of suppressing Fas ligand-induced apoptosis to a high degree, especially humanized antibodies having less antigenecity to human, and a method for assaying the Fas ligand in human body fluid utilizing such an antibody. Measurement of the Fas ligand in human body fluid would be useful for elucidation of hepatitis B, hepatitis C, HIV infections and the like, and for prediction and diagnosis of pathological conditions associated with such diseases.

Anti-Fas ligand antibody and assay method using the anti-Fas ligand

An agent for preventing or treating AIDS which contains as its effective component an anti-Fas ligand antibody, and the method for preventing and treating AIDS by using such drug.

Agent for suppressing a reduction of CD4.sup.+ lymphocytes

Growing community of inventors

Tokyo, Japan

Tomokazu Matsusue